Brainstorm Cell (BCLI) - Year-over-year earnings per share growth for the last twelve months
Brainstorm Cell (BCLI) operates a business that is extremely vulnerable due to its reliance on a single drug, a fact underscored by the quarterly EPS growth rate. The value of 0.00 determines the latest metric for assessing fundamental strength. Revenues are based on the commercialization of NurOwn for the treatment of ALS. High testing costs and biomaterial patents create a steep barrier to entry in this elite neuromedicine sector.
BrainStorm Cell Therapeutics Inc. (BCLI) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization indicators:
- book capitalization data:
- debt level and financial liquidity data:
Debt to Equity Brainstorm Cell|BCLI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Brainstorm Cell|BCLI - Company Total Debt|Debt to Book Value Brainstorm Cell|BCLI - Company Long-Term Loans and Borrowings|Company Short-Term Debts BrainStorm Cell Therapeutics|Quick Ratio brainstorm-cell.com
- earnings and valuation multiples information:
BCLI - Company Net Income|Expected Profit Brainstorm Cell|BCLI - Price to Earnings Ratio|Future Price to Earnings Brainstorm Cell Therapeutics, Inc.|BCLI - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Brainstorm Cell|BCLI - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) BrainStorm Cell Therapeutics|BCLI - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months brainstorm-cell.com|BCLI - Earnings per share growth in current year|Earnings growth forecast for next year Brainstorm Cell
Basic company analysis:BrainStorm Cell Therapeutics, BCLI
This indicator measures the quarterly rate of change in earnings per share, allowing investors to assess the actual efficiency of profit generation relative to the volume of capital. The seamless optimization of cold chain logistics for cellular materials converts directly into operational resilience, confirming the quarterly growth in EPS and testifying to the high fundamental strength of the Brainstorm Cell business.
Who Brainstorm Cell competes with
Biogen (BIIB) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months NBIX|Year-over-year earnings per share growth for the last twelve months Regencell|Axsome Corp (AXSM) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals)|Year-over-year earnings per share growth rate for the last twelve months XENE|Year-over-year earnings per share growth for the last twelve months Viking Therapeutics, Inc. VKTX|Supernus Pharmaceuticals, Inc. (SUPN) - Earnings per share growth in annualized terms for the last twelve months|CPRX - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Corp)|Harmony Biosciences (HRMY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months biohavenpharma.com|Year-over-year net earnings per share growth for the last 12 months AMLX|TRVI: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth PRAX|Year-over-year net earnings per share growth for the last 12 months Anavex Life Sciences Corp AVXL|Quarterly EPS earnings growth CBLL (CeriBell, Inc.)|prothena.com (PRTA) - Earnings per share growth in annualized terms for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|ANNX: Year-over-year earnings per share growth for the last twelve months|omeros.com (OMER) - Year-over-year earnings per share growth for the last twelve months|NGNE (Neurogene Therapeutics) - Year-over-year earnings per share growth for the last twelve months|ACIU (AC Immune) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months VYGR|Quarterly EPS earnings growth NMRA|Year-over-year net earnings per share growth for the last 12 months Scilex Holding SCLX|Year-over-year earnings per share growth for the last twelve months Tevogen Bio Holdings, Inc. TVGN|Alpha Cognition Inc - Year-over-year earnings per share growth for the last twelve months|Cognition Therapeutics, Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months inhibikase.com IKT|Cassava Sciences (SAVA) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months ASRT|COYA (Coya Therapeutics Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months VistaGen Therapeutics Inc VTGN|Year-over-year net earnings per share growth for the last 12 months OVID (Ovid Therapeutics Inc.)|Quarterly EPS earnings growth acumenpharm.com (ABOS)|Year-over-year earnings per share growth for the last twelve months CervoMed CRVO|Year-over-year earnings per one share growth for the last 12 months ATHE|CLNN - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months PepGen Inc.|JUNS: Quarterly EPS earnings growth|RLMD (relmada.com) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Annovis Bio|GRCE: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AIFF|Quarterly EPS earnings growth anewmeds.com (KLTO)|Quarterly EPS earnings growth NRSN (NeuroSense Therapeutics Ltd.)|Year-over-year net earnings per share change for the last twelve months revivapharma.com (RVPH)|MTVA - Year-over-year earnings per share growth for the last twelve months|NRXS (NeurAxis Inc.) - Year-over-year earnings per share growth for the last 12 months|heliusmedical.com (HSDT) - Year-over-year earnings per share growth for the last twelve months|PASG - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months NEUP|NERV (minervaneurosciences.com) - Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months Athira Pharma (ATHA)|ADXN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Alzamend Neuro ALZN|Year-over-year earnings per one share growth for the last 12 months CYCN|PTIX - Year-over-year earnings per share growth for the last twelve months|Pasithea Therapeutics (KTTA) - Year-over-year net earnings per share growth for the last 12 months|CRGT (cortigent.com) - Year-over-year net earnings per share growth for the last 12 months|Avenue Therapeutics Inc. - Year-over-year earnings per one share growth for the last 12 months|CARA (Cara Therapeutics, Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Chromocell (CHRO)|Quarterly EPS earnings growth ELYM|ITCI - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Longboard Pharmaceuticals, Inc. LBPH|Marinus Pharmaceuticals Inc - Year-over-year earnings per share growth for the last twelve months|NKGN - Year-over-year earnings per share growth for the last twelve months|NRBO: Year-over-year earnings per share growth for the last twelve months|SAGE: Quarterly EPS earnings growth|SNPX (synaptogen.com) - Year-over-year earnings per share growth for the last twelve months|TRVN (Trevena) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Vigil Neuro (VIGL)|Year-over-year earnings per share growth for the last twelve months Anew Medical, Inc. (WENA)|Year-over-year earnings per share growth for the last twelve months CERE (Cerevel Corp)
